Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma

NCT04291885 is registered in ClinicalTrials.gov with Melanoma and Skin Cancer Trials Limited as lead sponsor.

NCT NCT04291885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04291885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 26, 2020
Completion date
April 30, 2030
Enrollment
122 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma neuroendocrine skin, merkel cell carcinoma, merkel cell carcinoma, stage i, merkel cell carcinoma, stage ii, merkel cell carcinoma, stage iii, neuroendocrine tumors